TG Therapeutics CEO to Present at Jefferies Global Healthcare Conference
Event summary
- TG Therapeutics CEO Michael S. Weiss to participate in Jefferies Global Healthcare Conference on June 3, 2026.
- Fireside chat scheduled for 11:40 AM ET at Marriott Marquis, New York City.
- Live webcast available on TG Therapeutics' Investors & Media page.
- TG Therapeutics focuses on B-cell diseases, with FDA-approved BRIUMVI® for relapsing forms of multiple sclerosis.
The big picture
TG Therapeutics' participation in the Jefferies Global Healthcare Conference comes as the biotech firm seeks to solidify its position in the B-cell disease treatment space. With BRIUMVI® already approved by the FDA and several international regulatory agencies, the company is likely to emphasize its commercialization strategy and pipeline advancements. The event provides a platform to engage with key investors and industry stakeholders amid growing competition in the multiple sclerosis treatment landscape.
What we're watching
- Strategic Messaging
- How TG Therapeutics positions BRIUMVI® in a competitive multiple sclerosis market.
- Investor Sentiment
- Whether the presentation shifts investor perception of TG Therapeutics' growth trajectory.
- Regulatory Dynamics
- The pace at which TG Therapeutics expands BRIUMVI® approvals globally.
Related topics